SCHEMBL5222887

SCHEMBL5222887

COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(OC)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.69
KLKB1 P03952 1/20 0.67
KMT2A Q03164 6/20 0.62
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
HDAC1 Q13547 2/20 0.61
HDAC3 O15379 1/20 0.61
HDAC4 P56524 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC10 Q969S8 1/20 0.61
HDAC11 Q96DB2 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
HDAC5 Q9UQL6 1/20 0.61
MAPT P10636 3/20 0.57
ALDH1A1 P00352 2/20 0.56
TP53 P04637 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3783197 0.87 F10 (0.68) F10KLKB1KMT2ANPC1RAB9A
SCHEMBL5221640 0.86 F10 (0.81) F10KMT2ANPC1RAB9AHDAC1
SCHEMBL7249253 0.85 F10 (0.69) F10KMT2ANPC1RAB9AHDAC1
SCHEMBL9979760 0.85 F10 (0.56) F10KLKB1KMT2ANPC1RAB9A
SCHEMBL9979791 0.84 HDAC1 (0.63) F10KLKB1KMT2ANPC1RAB9A
SCHEMBL3794444 0.83 F10 (0.76) F10KMT2ANPC1RAB9AHDAC1
SCHEMBL3786312 0.83 F10 (0.66) F10KLKB1KMT2ANPC1RAB9A
SCHEMBL205172 0.83 PTPN11 (0.62) F10KLKB1KMT2ANPC1RAB9A
SCHEMBL2230035 0.82 F10 (1.00) F10KLKB1
Darexaban SCHEMBL2227024 0.82 F10 (1.00) F10KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 F10 12/4885KLKB1 210/4885KMT2A 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.